ERI1: A Potential Drug Target for Various Diseases (G90459)

Target Name: ERI1

NCBI ID: G90459

ERI1

ERI1: A Potential Drug Target for Various Diseases

ERI1 (ERI1-HUMAN), a protein that belongs to the ERI1 gene family, has been identified as a potential drug target or biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression patterns make it an attractive target for researchers to investigate and develop new treatments.

The ERI1 gene is located on chromosome 6p21.2 and encodes a protein that is expressed in various tissues and organs, including the brain, spinal cord, heart, kidneys, and liver. The protein has a molecular weight of approximately 11 kDa and consists of 110 amino acid residues.

The ERI1 protein is involved in various cellular processes, including cell adhesion, migration, and invasion. It plays a critical role in the development and maintenance of neural stem cells, which are a vital source of neural diversity and repair. ERI1 has been shown to regulate the sprouting angiogenesis that occurs during the development of neural stem cells, leading to the formation of new blood vessels and the growth of collateral vessels.

In addition to its role in neural development, ERI1 is also involved in the regulation of inflammation and immune responses. It has been shown to play a key role in the regulation of T cell responses during both adaptive and innate immune responses. ERI1 has been shown to interact with various immune molecules, including TGF-β, NF-kappa-B, and MAPK, to regulate immune cell function and to modulate the inflammatory response.

The potential drug target status of ERI1 is based on its involvement in various diseases and its unique expression patterns. ERI1 has been shown to be overexpressed or underexpressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its overexpression has been associated with the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its underexpression has been associated with the regulation of immune cell function and the development of various diseases, including cancer.

The potential drug targets for ERI1 include the regulation of its expression, the inhibition of its function, and the combination of both approaches to treat various diseases. The inhibition of ERI1 function has been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, ERI1 (ERI1-HUMAN) is a protein that has been identified as a potential drug target or biomarker in various diseases. Its unique structure and expression patterns make it an attractive target for researchers to investigate and develop new treatments. Further studies are needed to fully understand the role of ERI1 in various diseases and to develop effective treatments based on its unique properties.

Protein Name: Exoribonuclease 1

Functions: RNA exonuclease that binds to the 3'-end of histone mRNAs and degrades them, suggesting that it plays an essential role in histone mRNA decay after replication (PubMed:14536070, PubMed:16912046, PubMed:17135487). A 2' and 3'-hydroxyl groups at the last nucleotide of the histone 3'-end is required for efficient degradation of RNA substrates (PubMed:14536070, PubMed:16912046, PubMed:17135487). Also able to degrade the 3'-overhangs of short interfering RNAs (siRNAs) in vitro, suggesting a possible role as regulator of RNA interference (RNAi) (PubMed:14961122). Required for binding the 5'-ACCCA-3' sequence present in stem-loop structure (PubMed:14536070, PubMed:16912046). Able to bind other mRNAs (PubMed:14536070, PubMed:16912046). Required for 5.8S rRNA 3'-end processing (By similarity). Also binds to 5.8s ribosomal RNA (By similarity). Binds with high affinity to the stem-loop structure of replication-dependent histone pre-mRNAs (PubMed:14536070, PubMed:17135487, PubMed:16912046). In vitro, does not have sequence specificity (PubMed:17135487). In vitro, has weak DNA exonuclease activity (PubMed:17135487). In vitro, shows biphasic kinetics such that there is rapid hydrolysis of the last three unpaired RNA nucleotides in the 39 flanking sequence followed by a much slower cleavage through the stem that occurs over a longer incubation period in the order of hours (PubMed:17135487)

The "ERI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets